Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease.

ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia share underlying pathophysiological mechanisms and can bidirectionally influence the development and progression of each other. Diagnosing sarcopenia in individuals with MASLD is challenging due to overlapping symptoms and the frequent requirement for expensive, specialized equipment for muscle mass assessment. Therefore, accessible screening methods are crucial. Serum indices based on creatinine (Cr) and cystatin C (CysC), including Calculated Body Muscle Mass (CBMM), Sarcopenia Index (SI), and estimated glomerular filtration rate (eGFR) ratio, have emerged as potential biomarkers for sarcopenia. This study aimed to compare the performance of these serum indices in screening for low skeletal muscle index (SMI)

SUBMITTER: Hwang I 

PROVIDER: S-EPMC12367731 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature